Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Lemaitre Vascular (LMAT) over the last 17 years, with Q3 2025 value amounting to $25.5 million.

  • Lemaitre Vascular's Cash & Equivalents rose 2139.42% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 2139.42%. This contributed to the annual value of $25.6 million for FY2024, which is 552.56% up from last year.
  • Lemaitre Vascular's Cash & Equivalents amounted to $25.5 million in Q3 2025, which was up 2139.42% from $27.2 million recorded in Q2 2025.
  • Lemaitre Vascular's 5-year Cash & Equivalents high stood at $27.2 million for Q2 2025, and its period low was $13.9 million during Q4 2021.
  • Over the past 5 years, Lemaitre Vascular's median Cash & Equivalents value was $21.0 million (recorded in 2024), while the average stood at $21.1 million.
  • The largest annual percentage gain for Lemaitre Vascular's Cash & Equivalents in the last 5 years was 11495.8% (2021), contrasted with its biggest fall of 4823.27% (2021).
  • Over the past 5 years, Lemaitre Vascular's Cash & Equivalents (Quarter) stood at $13.9 million in 2021, then skyrocketed by 38.1% to $19.1 million in 2022, then grew by 26.84% to $24.3 million in 2023, then increased by 5.53% to $25.6 million in 2024, then decreased by 0.45% to $25.5 million in 2025.
  • Its Cash & Equivalents was $25.5 million in Q3 2025, compared to $27.2 million in Q2 2025 and $25.3 million in Q1 2025.